Chemours Financials - Benzinga

The Chemours Co

CCNYSE

Trade with Public

Trade with Public

$15.62

-0.26-1.64%

At close: Aug 28, 5:00 PM EST

$15.70

0.080.51%

After Hours: 5:40 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Dividends Compare Options Stock Report

Chemours Financials

Chemours (CC) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Chemours Widens FY2026 Sales Guidance from $5.982B-$6.098B to $5.866B-$6.098B vs $6.044B Est

Chemours (NYSE:CC) widens FY2026 sales outlook from $5.982 billion-$6.098 billion to $5.866 billion-$6.098 billion vs $6.044 billion estimate.

Benzinga Newsdesk

PRO
Chemours Sees Q3 Sales $1.511B-$1.591B vs $1.601B Est

Chemours (NYSE:CC) sees Q3 sales of $1.511 billion-$1.591 billion vs $1.601 billion analyst estimate.

Benzinga Newsdesk

PRO
Chemours Q2 Adj. EPS $0.42, Inline, Sales $1.591B Miss $1.654B Estimate

Chemours (NYSE:CC) reported quarterly earnings of $0.42 per share which met the analyst consensus estimate. This is a 27.59 percent decrease over earnings of $0.58 per share from the same period last year. The company

Benzinga Newsdesk

PRO
Chemours Affirms FY2026 Sales Guidance of $5.982B-$6.098B vs $5.987B Est

Full Year 2026 Outlook The Company continues to expect 2026 Net Sales to grow in the range of 3% to 5% over 2025, with Adjusted EBITDA between $800 million and $900 million. This outlook is supported by higher TSS

Benzinga Newsdesk

PRO
Chemours Sees Q2 2026 Sales $1.588B-$1.657B vs $1.655B Est

Second Quarter 2026 Outlook In the second quarter, the Company anticipates consolidated Net Sales to increase in the range of 15% to 20% sequentially, driven by favorable seasonal trends, with consolidated Adjusted

Benzinga Newsdesk

PRO
Chemours Q1 Adj. EPS $0.05 Beats $(0.05) Estimate, Sales $1.381B Miss $1.387B Estimate

Benzinga Newsdesk